Literature DB >> 21279518

PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis.

Matteo Fassan1, Marco Pizzi, Luciano Giacomelli, Claudia Mescoli, Kathrin Ludwig, Salvatore Pucciarelli, Massimo Rugge.   

Abstract

Programmed cell death 4 (PDCD4) has recently been demonstrated to be a new tumor suppressor gene involved in colon carcinogenesis. PDCD4 immunohistochemical expression was assessed in 300 polypoid lesions of the colon mucosa (50 hyperplastic polyps [HP], 50 serrated adenomas [SA], 50 tubular adenomas with low-grade-intraepithelial neoplasia [LG-IEN], 50 tubular adenomas with high-grade-IEN [HG-IEN]), and in 50 colon adenocarcinomas (CRC). As normal controls, we considered 50 biopsy samples obtained from patients with irritable bowel syndrome (N). We further investigated PDCD4 messenger RNA (mRNA) levels by quantitative real-time polymerase chain reaction (PCR) in a different series of N, LG-IEN, HG-IEN, and CRC biopsy samples. miR-21 expression (an important PDCD4-expression regulator) was also determined by quantitative real-time PCR and in situ hybridization. Normal colocytes and HP featured strong PDCD4 nuclear immunostaining whereas a significantly lower PDCD4 nuclear expression was observed in dysplasia (low- and high-grade adenomas and SA) and invasive CRC. PDCD4 immunostaining and mRNA levels decreased significantly as the phenotypic changes occurring during colon carcinogenesis progressively increased (p < 0.001). As expected, miR-21 expression was significantly upregulated in preneoplastic/neoplastic samples, consistent with PDCD4 downregulation. These results consistently support the use of nuclear PDCD4 immunohistochemical downregulation as a novel biomarker for the diagnosis of dysplastic/neoplastic lesions in colon biopsy samples.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21279518     DOI: 10.1007/s00428-011-1046-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  40 in total

1.  Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody.

Authors:  H Yoshinaga; S Matsuhashi; C Fujiyama; Z Masaki
Journal:  Pathol Int       Date:  1999-12       Impact factor: 2.534

Review 2.  Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening.

Authors:  Robert A Smith; Vilma Cokkinides; Durado Brooks; Debbie Saslow; Otis W Brawley
Journal:  CA Cancer J Clin       Date:  2010 Mar-Apr       Impact factor: 508.702

Review 3.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

4.  Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.

Authors:  Aaron P Jansen; Corinne E Camalier; Nancy H Colburn
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

5.  Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma.

Authors:  Patricia P Reis; Miranda Tomenson; Nilva K Cervigne; Jerry Machado; Igor Jurisica; Melania Pintilie; Mahadeo A Sukhai; Bayardo Perez-Ordonez; Reidar Grénman; Ralph W Gilbert; Patrick J Gullane; Jonathan C Irish; Suzanne Kamel-Reid
Journal:  Mol Cancer       Date:  2010-09-10       Impact factor: 27.401

6.  Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon.

Authors:  Tong-Tong Zou; Florin M Selaru; Yan Xu; Valentina Shustova; Jing Yin; Yuriko Mori; David Shibata; Fumiaki Sato; Suma Wang; Andreea Olaru; Elena Deacu; Thomas C Liu; John M Abraham; Stephen J Meltzer
Journal:  Oncogene       Date:  2002-07-18       Impact factor: 9.867

7.  Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.

Authors:  Olubunmi Afonja; Dominique Juste; Sharmistha Das; Sachiko Matsuhashi; Herbert H Samuels
Journal:  Oncogene       Date:  2004-10-21       Impact factor: 9.867

Review 8.  Reducing the incidence and mortality of colon cancer: mass screening and colonoscopic polypectomy.

Authors:  Mitchell S Cappell
Journal:  Gastroenterol Clin North Am       Date:  2008-03       Impact factor: 3.806

Review 9.  Progress and challenges in colorectal cancer screening and surveillance.

Authors:  David Lieberman
Journal:  Gastroenterology       Date:  2010-02-16       Impact factor: 22.682

10.  Dysregulation of the annexin family protein family is associated with prostate cancer progression.

Authors:  Wei Xin; Daniel R Rhodes; Collette Ingold; Arul M Chinnaiyan; Mark A Rubin
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

View more
  40 in total

1.  MicroRNA MIR21 and T Cells in Colorectal Cancer.

Authors:  Kosuke Mima; Reiko Nishihara; Jonathan A Nowak; Sun A Kim; Mingyang Song; Kentaro Inamura; Yasutaka Sukawa; Atsuhiro Masuda; Juhong Yang; Ruoxu Dou; Katsuhiko Nosho; Hideo Baba; Edward L Giovannucci; Michaela Bowden; Massimo Loda; Marios Giannakis; Adam J Bass; Glenn Dranoff; Gordon J Freeman; Andrew T Chan; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Cancer Immunol Res       Date:  2015-09-29       Impact factor: 11.151

2.  Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia.

Authors:  Atsushi Yamada; Takahiro Horimatsu; Yoshinaga Okugawa; Naoshi Nishida; Hajime Honjo; Hiroshi Ida; Tadayuki Kou; Toshihiro Kusaka; Yu Sasaki; Makato Yagi; Takuma Higurashi; Norio Yukawa; Yusuke Amanuma; Osamu Kikuchi; Manabu Muto; Yoshiyuki Ueno; Atsushi Nakajima; Tsutomu Chiba; C Richard Boland; Ajay Goel
Journal:  Clin Cancer Res       Date:  2015-06-02       Impact factor: 12.531

Review 3.  The role of microRNAs in cancers of the upper gastrointestinal tract.

Authors:  Shumei Song; Jaffer A Ajani
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-20       Impact factor: 46.802

4.  MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.

Authors:  Caterina Mian; Gianmaria Pennelli; Matteo Fassan; Mariangela Balistreri; Susi Barollo; Elisabetta Cavedon; Francesca Galuppini; Marco Pizzi; Federica Vianello; Maria Rosa Pelizzo; Maria Elisa Girelli; Massimo Rugge; Giuseppe Opocher
Journal:  Thyroid       Date:  2012-06-29       Impact factor: 6.568

Review 5.  miRNAs in precancerous lesions of the gastrointestinal tract.

Authors:  Matteo Fassan; Carlo M Croce; Massimo Rugge
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

6.  PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis.

Authors:  Kathrin Ludwig; Matteo Fassan; Claudia Mescoli; Marco Pizzi; Mariangela Balistreri; Laura Albertoni; Salvatore Pucciarelli; Marco Scarpa; Giacomo Carlo Sturniolo; Imerio Angriman; Massimo Rugge
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

7.  Programmed cell death 4 mechanism of action: The model to be updated?

Authors:  Polina N Vikhreva; Svetlana V Kalinichenko; Igor V Korobko
Journal:  Cell Cycle       Date:  2017-08-30       Impact factor: 4.534

Review 8.  The critical roles of miR-21 in anti-cancer effects of curcumin.

Authors:  Jiezhong Chen; Tiefeng Xu; Chen Chen
Journal:  Ann Transl Med       Date:  2015-12

9.  Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer.

Authors:  Yuji Toiyama; Masanobu Takahashi; Keun Hur; Takeshi Nagasaka; Koji Tanaka; Yasuhiro Inoue; Masato Kusunoki; C Richard Boland; Ajay Goel
Journal:  J Natl Cancer Inst       Date:  2013-05-23       Impact factor: 13.506

10.  PDCD4 expression in thyroid neoplasia.

Authors:  Gianmaria Pennelli; Matteo Fassan; Caterina Mian; Marco Pizzi; Mariangela Balistreri; Susi Barollo; Francesca Galuppini; Vincenza Guzzardo; Mariarosa Pelizzo; Massimo Rugge
Journal:  Virchows Arch       Date:  2012-12-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.